GTC Biotherapeutics (fka GTCB)

[krenjp]

"The first quarter 2008 research and development expenses also included $5.1 million of expense related to the ATryn program, compared with $4.7 million in the first quarter of 2007. These expenses included cost to manufacture ATryn in excess of the maximum selling price to LEO..."

I am probably not reading this correctly; does the last line mean that manufacturing Atryn costs more than the selling price to LEO???